AMRN - Amarin inks licensing deal with Recordati for lead drug Vazkepa June, 24 2025 07:40 AM Amarin Corporation plc 2025-06-24 07:40:11 ET More on Amarin Amarin Is A Sell Despite The Large Cash Balance Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript Amarin Corporation plc 2025 Q1 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Amarin Historical earnings data for Amarin For further details see: Amarin inks licensing deal with Recordati for lead drug Vazkepa